XOMA (NASDAQ:XOMA) Downgraded by StockNews.com to Sell

XOMA (NASDAQ:XOMA - Get Free Report) was downgraded by equities research analysts at StockNews.com from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Wednesday.

Separately, HC Wainwright reiterated a "buy" rating and issued a $123.00 price target on shares of XOMA in a research note on Tuesday.

XOMA Price Performance

XOMA stock traded up $0.07 during trading on Wednesday, reaching $25.74. 18,085 shares of the company were exchanged, compared to its average volume of 34,277. The company has a market capitalization of $303.29 million, a price-to-earnings ratio of -7.40 and a beta of 0.92. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52. The company has a 50-day moving average of $29.28 and a two-hundred day moving average of $27.95. XOMA has a twelve month low of $18.57 and a twelve month high of $35.00.

Insider Buying and Selling at XOMA

In other XOMA news, CEO Owen Hughes sold 21,881 shares of XOMA stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total transaction of $655,335.95. Following the transaction, the chief executive officer now directly owns 34,979 shares of the company's stock, valued at approximately $1,047,621.05. The trade was a 38.48 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 7.20% of the company's stock.

Hedge Funds Weigh In On XOMA

A number of hedge funds and other institutional investors have recently made changes to their positions in XOMA. Bank of New York Mellon Corp raised its stake in XOMA by 3.2% during the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company's stock worth $1,484,000 after buying an additional 1,968 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of XOMA by 16.0% in the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company's stock valued at $230,000 after purchasing an additional 1,334 shares during the period. Ellsworth Advisors LLC acquired a new position in shares of XOMA in the 3rd quarter valued at about $516,000. BNP Paribas Financial Markets boosted its position in shares of XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company's stock valued at $43,000 after purchasing an additional 795 shares in the last quarter. Finally, State Street Corp increased its holdings in XOMA by 1.2% in the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company's stock worth $3,783,000 after purchasing an additional 1,754 shares in the last quarter. 95.92% of the stock is owned by institutional investors and hedge funds.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.